Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab

References

• Anderson D R, Grillo-Lopez A, Varns C, Chambers K S, Hanna N. Targeted anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997; 25: 705–708
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri G-M, Bernasconi S, et al. Biological response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900–3908
   PubMed Web of Science ®Google Scholar
• Weng W-K, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 2001; 98: 1352–1357
   PubMed Web of Science ®Google Scholar
• Manches O, Lui G, Chaperot L, Gressin R, Molens J-P, Jacob M-C, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101: 949–954
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγR IIIa gene. Blood 2002; 99: 754–758
   PubMed Web of Science ®Google Scholar
• Weng W-K, Levy R. Two immunoglobulin G Fc receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940–3947
   PubMed Web of Science ®Google Scholar
• Fanger M W, Shen L, Graziano R F, Guyre P M. Cytotoxicity mediated by human Fc receptors for IgG. Trend Immunol 1989; 10: 92–99
   Web of Science ®Google Scholar
• Graziano R F, Ranger M W. FcγRI and FcγRII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells. J Immunol 1987; 139: 3536–3541
   PubMed Web of Science ®Google Scholar
• Koene H R, Kleijer M, Algra J, Roos D, von dem Borne A, de Haas M. FcγRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48 L/R/H phenotype. Blood 1997; 90: 1109–1114
   PubMed Web of Science ®Google Scholar
• Shields R L, Namenuk A K, Hong K, Meng Y G, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 2001; 276: 6591–6604
   PubMed Web of Science ®Google Scholar
• Vance B A, Huizinga T WJ, Wardwell K, Guyre P M. Binding of monomeric human IgG defines an expression polymorphism of FcγRIII on large granular lymphocyte/natural killer cells. J Immunol 1993; 151: 6429–6439
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch J V. Fcγ receptors: old friends and new family members. Immunity 2006; 24: 19–28
   PubMed Web of Science ®Google Scholar
• Kyogoku C, Dijstelbloem H M, Tsuchiya N, Hatta Y, Yamaguchi A, Fukazawa T, et al. Fcγ receptor gene polymorphism in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum 2002; 46: 1242–1254
   PubMed Web of Science ®Google Scholar
• Li X, Wu J, Carter R H, Edberg J C, Su K, Cooper G S, et al. A novel polymorphism in the Fcγ receptor IIB (CD32B) transmembrane region alters receptor signaling. Arthritis Rheum 2003; 48: 3242–3252
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Kopreski M S, Benko F A, Kwee C, Leitzel K E, Eskander E, Lipton A, et al. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer 1997; 76: 1293–1299
   PubMed Web of Science ®Google Scholar
• Clynes R A, Towers T L, Presta L G, Ravetch J V. Inhibitory Fc receptor modulate in vivo cytotoxicity against tumor targets. Nature Med 2000; 6: 443–446
   PubMed Web of Science ®Google Scholar
• Kono H, Kyogoku C, Suzuki T, Tsuchiya N, Honda H, Yamamoto K, et al. FcγRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Human Mol Gene 2005; 14: 2881–2892
   PubMed Web of Science ®Google Scholar
• Camilleri-Broet S, Mounier N, Delmer A, Briere J, Casasnovas O, Cassard L, et al. FcγRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP + rituximab (R-CHOP). Leukemia 2004; 18: 2038–2040
   PubMed Web of Science ®Google Scholar
• Lejeune J, Thibault G, Ternant D, Cartron G, Watier H, Ohresser M. Evidence for linkage disequilibrium between FcγRIIIa-V158F and FcγRIIA-H131R polymorphisms in white patients, and for an FcγIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol 2008; 26: 5489–5491
   PubMed Web of Science ®Google Scholar
• van der Pol W L, Jansen M D, Sluiter W J, van de Sluis B, Leppers-van de Straat F GJ, Kobayashi T, et al. Evidence for non-random distribution of Fcγ receptor genotype combinations. Immunogenetics 2003; 55: 240–246
   PubMed Web of Science ®Google Scholar
• Miescher S, Spycher M O, Amstutz H, de Haas M, Kleijer M, Kalus U J, et al. A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphism in the FcγRIIA and FcγRIIIA genes. Blood 2004; 103: 4028–4035
   PubMed Web of Science ®Google Scholar
• Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragement C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789–1796
   PubMed Web of Science ®Google Scholar
• Zhang W, Gordon M, Schultheis A M, Yang D Y, Nagashima F, Azuma M, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor-expression metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25: 3712–3718
   PubMed Web of Science ®Google Scholar
• Weng W-K, Czerwinski D, Timmerman J, Hsu F J, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004; 22: 4717–4724
   PubMed Web of Science ®Google Scholar
• Chu Z T, Tsuchiya N, Kyogoku C, Ohashi J, Wian Y P, Xu S B, et al. Association of Fcγ receptor IIb polymorphism with susceptibility to systemic lupus erythematosus in Chinese: a common susceptibility gene in the Asian populations. Tissue Antigens 2004; 63: 21–27
   PubMed Web of Science ®Google Scholar